Results 131 to 140 of about 1,692 (164)

Prasterone: A Review in Vulvovaginal Atrophy

Drugs & Aging, 2019
Vulvovaginal atrophy (VVA) is a progressive condition commonly seen in postmenopausal women. The cessation of ovarian estrogen secretion and a fall in serum levels of dehydroepiandrosterone (DHEA), the remaining source of estrogens and androgens, are thought to promote the development of VVA in this population. Intravaginal prasterone (Intrarosa®) is a
openaire   +2 more sources

Treatment of Dyspareunia Secondary to Vulvovaginal Atrophy

Nursing for Women's Health, 2014
Declining estrogen levels associated with menopause can result in vulvovaginal atrophy and some degree of dyspareunia for more than half of all women in menopause. In 2013, the U.S. Food and Drug Administration approved ospemifene, a nonhormonal oral medication for the treatment of dyspareunia in menopause.
openaire   +2 more sources

Managing vulvovaginal atrophy after breast cancer

Post Reproductive Health, 2018
Cancer treatment may result in loss of ovarian function through surgical removal of the ovaries, chemotherapy or radiation. While menopausal symptoms, such as hot flushes, night sweats, sleep disturbance, memory concerns and mood issues can be extremely bothersome to some women going through menopause naturally, women who undergo an induced menopause ...
Jenifer, Sassarini, Mahesh, Perera, Keith, Spowart, Kay, McAllister, Judith, Fraser, Ros, Glasspool, Rosie, Harrand, Marina, Chitoni, Sheila, Stallard, Mary-Ann, Lumsden   +9 more
openaire   +2 more sources

Rehabilitation of patients with vulvovaginal atrophy

Journal of Medical Rehabilitation
Background. Genitourinary syndrome of menopause (GSM) is characterized by a number of pathological changes, in particular urological disorders, vulvovaginal atrophy (VVA) and sexual dysfunction. They are commonly accompanied by decreased quality of life (QoL) and often require medical intervention. At the same time, the steps taken to effectively solve
P. L. Khazan, A. N. Mnatsakanyan, D. I. Korabelnikov, D. M. Ampilogova, D. A. Petrenko   +4 more
openaire   +1 more source

Current treatment options for vulvovaginal atrophy

Expert Review of Obstetrics and Gynecology, 2011
Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide.
Rebekah Burich, Michael DeGregorio
exaly   +2 more sources

Ospemifene for the Treatment of Vulvovaginal Atrophy and Dyspareunia in Postmenopausal Women

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
Vulvovaginal atrophy (VVA) and dyspareunia are common problems experienced by postmenopausal women, although few seek treatment. Symptom‐based therapies include nonhormonal vaginal lubricants, vaginal moisturizers, low‐dose vaginal estrogen, and systemic estrogen.
Amber N, McLendon, Valerie B, Clinard, C Brock, Woodis   +2 more
openaire   +2 more sources

Laser Treatment for Vulvovaginal Atrophy

2019
Laser therapy has a therapeutic role for different medical conditions and most recently has gained interest as a non-hormonal treatment for vulvovaginal atrophy or genitourinary syndrome of menopause (GSM). Both microablative fractional CO2 laser and the second-generation non-ablative vaginal Er:YAG laser (VEL) can alleviate the symptoms of dryness and
openaire   +1 more source

A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy

Menopause, 2018
Abstract Objectives: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support ...
Robin J, Bell, Farwa, Rizvi, Rakabul M, Islam, Susan R, Davis   +3 more
openaire   +2 more sources

[Sulphurous vaginal douching and vulvovaginal atrophy].

La Clinica terapeutica, 2018
During climacteric the reduction or interruption of estrogenic stimulus determines a gradual atrophy of the tissues of the urogenital tract.Vulvovaginal atrophy can be cause of dryness, itch, burning, and dyspareunia. Vulvovaginal atrophy is associated also with depression.
M, Costantino, V, Conti, M B, Marongiu, G, Napolano, A, Filippelli   +4 more
openaire   +1 more source

Fractional CO2 Laser for Vulvovaginal Atrophy.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2018
To evaluate the short term efficacy and safety of Fractional CO2 laser for the treatment of vulvovaginal atrophy.From March 2015 to October 2015, 112 menopausal women were recruited. All women with VVA were treated by using Fractional CO2 laser; power 30 watts, 1-3 stacks with 360° vaginal probe for 3 consecutive times, 4 weeks apart.
Orawan, Lekskulchai, Karicha, Mairaing, Nipattha, Vinayanuvattikhun   +2 more
openaire   +1 more source